Krystal Biotech delivered strong financial results in Q4 2025, with VYJUVEK net product revenue reaching $107.1 million and a high gross margin of 94%. The company also made significant progress in its pipeline, securing RMAT designation for KB707 and Fast Track Designation for KB111, while maintaining a robust cash position.

Krystal Biotech delivered solid financial results for Q3 2025, driven by continued VYJUVEK revenue growth and expanded international reach. Net income more than doubled compared to the previous year, and the company ended the quarter with a robust cash position.

Krystal Biotech delivered a robust second quarter in 2025, with net product revenue reaching $96.0 million, primarily from VYJUVEK. The company achieved a net income of $38.3 million and an EPS of $1.29 (diluted). Key highlights include the approval of VYJUVEK in Japan and Europe, alongside advancements in its diverse pipeline across respiratory, ophthalmology, oncology, and aesthetics.

Krystal Biotech reported strong first-quarter 2025 results driven by VYJUVEK revenue, achieving $88.2 million in product sales and a net income of $35.7 million. The company also secured European approval for VYJUVEK and advanced its pipeline with a new ophthalmic program and upcoming clinical readouts.

Krystal Biotech posted a significant increase in Q4 2024 revenue, reaching $91.1 million, a 116% year-over-year growth. The company's net income also surged to $45.5 million, reflecting strong operational performance. Gross margin remained high at 95%, and the company closed the quarter with a robust cash and investment position of $749.6 million.

Krystal Biotech reported a net product revenue of $83.8 million for Q3 2024 and $250.1 million since the launch of VYJUVEK in August 2023. The company is progressing with its B-VEC filings in Japan and Europe, with commercial launches expected in 2025. A strong cash position of $694.2 million was maintained at the end of the quarter.

Krystal Biotech reported a strong second quarter with $70.3 million in VYJUVEK net product revenue, a 55.3% increase compared to the first quarter of 2024. The company is progressing with its clinical pipeline and anticipates multiple clinical data readouts in the second half of 2024. They ended the quarter with $628.9 million in cash and investments.

Krystal Biotech reported strong uptake of VYJUVEK and progress across its clinical pipeline in Q1 2024. Net product revenue was $45.3 million, and the company has $622.3 million in cash and investments.

Krystal Biotech reported Q4 net product revenue of $42.1 million from VYJUVEK sales and a net income of $8.7 million. The company closed the year with a strong balance sheet, holding $594.1 million in cash and investments.

Krystal Biotech reported its Q3 2023 financial results, featuring $8.6 million in VYJUVEK U.S. net product revenue, alongside advancements in their clinical programs for CF and oncology. The company closed the quarter with a strong cash position of $598.6 million.

Krystal Biotech announced positive Q2 2023 results, highlighted by the FDA approval of VYJUVEK, a topical gene therapy for dystrophic epidermolysis bullosa, and its subsequent commercial launch. The company also reported progress in its cystic fibrosis and oncology programs, with a strong balance sheet including $505.9 million in cash, cash equivalents, and investments.

Krystal Biotech reported a net loss of $45.3 million for the first quarter of 2023. The company's cash, cash equivalents, and investments totaled $355.5 million as of March 31, 2023. Significant progress was made in commercial preparation activities for B-VEC and advancements across the pipeline.

Krystal Biotech reported a net loss of $32.1 million for the fourth quarter of 2022, with cash, cash equivalents, and investments totaling $383.8 million. The company is focused on advancing B-VEC toward approval and expanding its gene delivery platform, with plans to have its second manufacturing facility operational soon.

Krystal Biotech reported a net loss of $29.9 million for the third quarter of 2022. The company's cash, cash equivalents, and investments totaled $407.0 million as of September 30, 2022. The company is preparing for the potential launch of B-VEC in the US and EU in 2023.

Krystal Biotech reported a net loss of $28.1 million for the second quarter of 2022. The company's cash, cash equivalents, and investments totaled $438.5 million as of June 30, 2022. The B-VEC BLA was filed with the FDA on June 22, 2022, and the FDA accepted the IND on KB407 for the treatment of Cystic Fibrosis.

Krystal Biotech reported a net loss of $50.0 million for the quarter ended March 31, 2022. The company's cash, cash equivalents, and investments totaled $468.0 million. A biologics license application for B-VEC remains on track to file in the US in 2Q 2022 and Marketing Authorization in the EU on track to file in 2H 2022.

Krystal Biotech reported positive topline data from the Phase 3 trial of VyjuvekTM for the treatment of dystrophic epidermolysis bullosa and is working towards global regulatory filings. The company's cash, cash equivalents and investments totaled $502.5 million on December 31, 2021.

Krystal Biotech reported a productive third quarter with progress in clinical trials, including the completion of the GEM-3 trial for B-VEC and advancements in other pipeline programs. The company's cash, cash equivalents, and investments totaled $362.3 million as of September 30, 2021.

Krystal Biotech reported financial results for the second quarter ending June 30, 2021. The company is advancing three clinical stage programs and made significant headway on the construction of its 2nd GMP manufacturing facility. Top-line data from the pivotal GEM-3 study of B-VEC in dystrophic epidermolysis bullosa is on track for 4Q21. Initiation of Phase 1 study of inhaled KB407 for the treatment of cystic fibrosis is expected in 3Q21.

Krystal Biotech reported financial results and key operational progress updates for the first quarter ending March 31, 2021. The company completed enrollment in the pivotal GEM-3 trial of B-VEC in dystrophic epidermolysis bullosa (DEB) and had cash, cash equivalents and short-term investments of $403.4 million.

Krystal Biotech reported its Q4 2020 financial results, with a strong cash position of $271.3 million in cash, cash equivalents and short-term investments. The company is progressing with its clinical trials, including B-VEC for DEB, KB105 for TGM1-ARCI, KB407 for Cystic Fibrosis and KB301 for Aesthetic Indications.

Krystal Biotech reported its Q3 2020 results, highlighting the initiation of pivotal trials for DEB, ARCI and aesthetic skin conditions. The company also announced positive preclinical data for KB407 in cystic fibrosis and reported a strong balance sheet with $286.4 million in cash, cash equivalents and short-term investments.

Krystal Biotech reported a net loss of $6.8 million for the second quarter of 2020. The company's cash, cash equivalents, and short-term investments totaled $297.2 million as of June 30, 2020. They are on track to initiate a Phase 1 trial of KB301 for an aesthetic indication in 2H 2020.

Krystal Biotech reported a net loss of $5.3 million, or $0.31 per share, for the first quarter ended March 31, 2020. The company ended the quarter with $186.7 million in cash, cash equivalents and short-term investments. Krystal Biotech is on track to start the B-VEC Phase 3 pivotal study in the first half of 2020.

Krystal Biotech reported its 2019 financial results, highlighting the commencement of the pivotal study for B-VEC and the anticipation of interim Phase 1/2 clinical results for KB105 in the first half of 2020. The company also broke ground on its second cGMP manufacturing facility, ASTRA, and strengthened its senior management team.